Therefore, although DGUOK‐targeted therapies in lung cancer patients may have potential side‐effects on mtDNA homeostasis in the liver, these side‐effects are possibly tolerable within a therapeutic window. This evidence concerns the gene DGUOK and lung carcinoma.